Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Trastuzumab deruxtecan yields promising results in HER2-positive breast cancer...

Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA

Trastuzumab deruxtecan yields promising results in HER2-positive breast cancer patients pretreated with TDM-1 ( Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA )

Umbralisib, ublituximab and venetoclax in patients with relapsed or refractory...

Dr Paul Barr - Wilmot Cancer Institute, University of Rochester Medical Center

$Umbralisib, ublituximab and venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia ( Dr Paul Barr - Wilmot Cancer Institute, University of Rochester Medical Center )$

Myeloma highlights from ASH 2019

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

Myeloma highlights from ASH 2019 ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )

Weekly wKRd-D in newly diagnosed multiple myeloma achieves unprecedented results

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

Weekly wKRd-D in newly diagnosed multiple myeloma achieves unprecedented results ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )

Chronic lymphocytic leukaemia highlights from ASH 2019

Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia

Chronic lymphocytic leukaemia highlights from ASH 2019 ( Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia )

Inotuzumab ozogamicin and chemotherapy with or without blinatumomab in...

Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA

Inotuzumab ozogamicin and chemotherapy with or without blinatumomab in Philadelphia chromosone-negative ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )

Updates on REGN1979 in R/R B-cell non-Hodgkins lymphoma

Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey, New Brunswick, USA

Updates on REGN1979 in R/R B-cell non-Hodgkins lymphoma ( Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey, New Brunswick, USA )

Eligibility criteria in acute myeloid leukaemia clinical trials

Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA

Eligibility criteria in acute myeloid leukaemia clinical trials ( Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA )

Azacitidine plus nivolumab in older adults with AML or MDS

Prof Annette Hay - Queen's University, Ontario, Canada

Azacitidine plus nivolumab in older adults with AML or MDS ( Prof Annette Hay - Queen's University, Ontario, Canada )

CARTITIUDE-1: BCMA-targeted CAR T-cell therapy shows high response rates in...

Prof Deepu Madduri - Mount Sinai, New York, USA

CARTITIUDE-1: BCMA-targeted CAR T-cell therapy shows high response rates in patients with multiple myeloma ( Prof Deepu Madduri - Mount Sinai, New York, USA )

Exploring the pathogenesis of AML and myelodysplastic syndromes using genome...

Dr Ilaria Iacobucci - St. Jude Children's Research Hospital, Memphis, USA

Exploring the pathogenesis of AML and myelodysplastic syndromes using genome and transcriptome sequencing ( Dr Ilaria Iacobucci - St. Jude Children's Research Hospital, Memphis, USA )

Carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

Carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )

More from ecancer